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Improved mechanistic understanding of renal cell death in
acute kidney injury (AKI) has generated new therapeutic
targets. Clearly, the classic lesion of acute tubular necrosis
is not adequate to describe the consequences of renal
ischemia, nephrotoxin exposure, or sepsis on glomerular
filtration rate. Experimental evidence supports a pathogenic
role for apoptosis in AKI. Interestingly, proximal tubule
epithelial cells are highly susceptible to apoptosis, and injury
at this site contributes to organ failure. During apoptosis,
well-orchestrated events converge at the mitochondrion, the
organelle that integrates life and death signals generated
by the BCL2 (B-cell lymphoma 2) protein family. Death
requires the ‘perfect storm’ for outer mitochondrial
membrane injury to release its cellular ‘executioners’. The
complexity of this process affords new targets for effective
interventions, both before and after renal insults. Inhibiting
apoptosis appears to be critical, because circulating factors
released by the injured kidney induce apoptosis and
inflammation in distant organs including the heart, lung,
liver, and brain, potentially contributing to the high
morbidity and mortality associated with AKI. Manipulation
of known stress kinases upstream of mitochondrial injury,
induction of endogenous, anti-apoptotic proteins, and
improved understanding of the timing and consequences
of renal cell apoptosis will inevitably improve the outcome
of human AKI.
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Nearly 20 years ago, a group of scientists reported apoptosis
after renal ischemia.1 Thereafter, several insightful reviews on
the role of apoptosis in acute kidney injury (AKI) have been
published.2–10 The purpose of this review is to discuss recent
observations that link apoptosis to the loss of organ function
after AKI and to introduce experimental antiapoptotic
therapies with the potential to preserve renal function after
an acute insult.
APOPTOSIS IN AKI
AKI is a common clinical complication characterized by an
abrupt decrease in the glomerular filtration rate (GFR).
Despite supportive care including renal replacement therapy,
the 5-year mortality after AKI remains B50%.3 The decline
in renal function results from cellular injury that precipitates
functional and structural changes in the kidney. A number of
pathologic processes contribute to AKI, including endothelial
and epithelial cell death, intratubular obstruction, changes in
local microvascular blood flow, as well as immunological and
inflammatory processes. The relative contribution of each to
the decline in GFR is uncertain. Limited understanding of the
cellular mechanisms of AKI complicates the development of
an effective treatment. Although renal epithelial cell necrosis
has long been regarded as the pathognomonic lesion of
ischemic AKI, the single most common etiology, the amount
of necrosis detected in human renal tissue fails to predict
renal function, the potential for recovery of native kidney
function, or the need for renal replacement therapy in either
native kidneys or allografts.11 The lack of correlation between
classic cell necrosis and organ function implicates alternative
forms of cell death as contributors to organ failure, and
investigators have increasingly recognized that renal cell
death also includes apoptosis and, possibly, autophagic cell
death.5,12 The delayed recognition that apoptosis contributes
to organ dysfunction is likely because of its stochastic nature,
the rapid disappearance of apoptotic cells, and insensitive
detection techniques.5,13 In spite of these difficulties in
reliably detecting apoptosis, this form of cell death correlates
far better with the level of renal dysfunction than necrosis—
at least in murine models of ischemic AKI.14–16
Several common renal insults cause apoptosis in the
kidney, including ischemia, toxic injury, radiation, and
ureteral obstruction. During embryonic development, the
apoptotic ‘cell death program’ plays a crucial role in normal
morphogenesis. Programmed apoptosis also promotes cell
turnover (during aging and for replacing malfunctioning or
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diseased cells) and during development of T and B
lymphocytes.17–20 In the healthy human adult, nearly 50–70
billion cells die an apoptotic death each day.21 Although this
‘programmed cell death’ is clearly necessary to maintain the
health of the organism, dysregulation of cell death by
excessive or defective apoptosis has been implicated in a
variety of disease states. Excessive apoptosis contributes to
atrophy and promotes fibrosis and organ dysfunction,22,23
whereas insufficient apoptosis facilitates unregulated cell
proliferation in most cancers. Dysregulation of apoptosis also
leads to chronic inflammatory and autoimmune diseases as
well as congenital anomalies.19,20,24,25
During apoptosis, regulated, energy-requiring biochemical
events cause characteristic morphologic changes including
plasma membrane blebbing, loss of cell membrane asym-
metry, cell shrinkage with ‘rounding’, cell detachment,
chromosomal DNA fragmentation, chromatin condensation,
and surface expression of opsonic receptors that allow
neighboring cells to rapidly phagocytose membrane-bound
chromatin fragments referred to as ‘apoptotic bodies’.26 These
morphologic changes represent the classic hallmarks of
apoptosis that are distinct from cell necrosis (Table 1).
Compared with necrosis, apoptosis confers advantages
to the injured organ. Necrosis results in rapid disintegration
of the plasma membrane, allowing toxic substances to be
released into the extracellular milieu that stimulate a marked
inflammatory response in the surrounding tissue. In contrast,
preservation of plasma membrane integrity coupled with the
rapid digestion of ‘apoptotic corpses’ by macrophages and
neighboring epithelial cells limit inflammatory cell recruit-
ment that would otherwise aggravate tissue damage. The
intrinsic and extrinsic variables that determine whether a cell
dies by apoptosis or necrosis are incompletely characterized.
However, both the severity27,28 and duration29 of adenosine-
50-triphosphate (ATP) depletion have been implicated as key
determinants of cell fate. If true, then local and regional
differences in the degree of adenosine nucleotide dysregula-
tion in the kidney could explain the observation that both
‘spotty’ apoptosis and necrosis coexist in close physical
proximity.1 Some investigators suggest that some apoptotic
cells are intrinsically unstable and undergo secondary
necrosis,5,30 further complicating accurate assessment of the
contribution of each to organ dysfunction. Despite these
limitations in separating the two cell death pathways,
therapeutic interventions that primarily inhibit apoptosis
have potential for minimizing renal dysfunction and accel-
erating recovery after AKI.
APOPTOSIS IN RENAL ISCHEMIC INJURY
Transient ischemia due to hypovolemia, hypotension, or
heart failure commonly causes AKI and accounts for nearly
one-third of patients requiring acute renal replacement
therapy. Of these insults, ischemia/reperfusion (I/R) are the
most well studied. In the isolated erythrocyte-perfused
kidney, proximal tubular epithelial cells are highly susceptible
cells to acute ischemia.5,31 Extensive evidence suggests that
detachment, dysfunction, and death of these cells is primarily
responsible for the pathophysiological and clinical aspects of
ischemic AKI,32 although inflammation is also prominent
and may partly mediate its duration and long-term
consequences.33 Under physiological conditions, proximal
tubule cells are columnar in shape with highly polarized
basal-lateral and apical surface membrane domains that drive
solute reabsorption or excretion. I/R variably causes some
cells to die by necrosis or apoptosis, whereas other cells
undergo sublethal injury. Loss of tubular cells leads to
unregulated paracellular diffusion of water, ions, and
macromolecules, thereby causing increased backleak, which
reduces GFR.32 Both lethally and sublethally damaged cells
enter the lumen along with apical membrane material and
other cellular debris and can aggregate (a process mediated by
the extrinsic RGD sequences within the extracellular domain
of b-integrin34) to form casts, resulting in tubular obstruc-
tion. Tubular obstruction further compromises organ func-
tion by increasing intratubular pressures to levels that are
inconsistent with filtration. Together, loss of cell surface
area and tubular obstruction decrease GFR. Reductions in
proximal tubule ion and water reabsorption result in high
distal delivery of Naþ , Kþ , Cl, and high distal flow rates.
In turn, tubuloglomerular feedback produces afferent
arteriole constriction and lowers GFR. Peritubular capillaries
may be congested with infiltrating leukocytes that impair
local renal blood flow, aggravating tubular ischemia. These
processes, along with endothelial cell injury, immunologic, or
Table 1 | Features of cell apoptosis versus necrosis
Apoptosis Necrosis
Energy requirement Yes No
Temperature
dependence
Inhibited at 4 1C Occurs at 4 1C
Cell morphology Cell shrinks and rounds
Apoptotic bodies—
membrane-bound
vesicles
Cell and organelle
swelling
Complete cell lysis
Membrane
alterations
Intact plasma membrane
Membrane blebbing
w/ phosphatidylserine
exposure
Plasma membrane
disintegrates
Nuclear morphology Chromatin condenses Nucleus swells
DNA injury Nonrandom mono-
and oligo-nucleosomal
length fragmentation
(‘ladder’ pattern per
agarose gel
electrophoresis)
Randomly sized
fragments (‘smear’
per agarose gel
electrophoresis)
Caspase activation Yes No
Inflammatory
response in the
surrounding tissue
Minimal Extensive
Regulation Tightly regulated
process involving
activation and enzymatic
steps requiring
adenosine-5’-
triphosphate (ATP)
Regulated ATP
negligible or absent
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inflammatory processes, contribute to the pathophysiological
consequences of ischemic AKI. The relative contribution of
each specific mechanism to loss of organ function in AKI is
uncertain and may depend on the type and severity of the
insult as well as the host’s inherent susceptibility to stress.
Many investigators believe that apoptosis significantly
contributes to ischemic renal dysfunction.5,8,13 This assertion
is based on reports showing that multiple approaches
(Hoechst staining, caspase 3 activation or activity, apoptosis-
inducing factor (AIF) or cytochrome c release, TUNEL (TdT-
mediated dUTP nick end labeling), conformational Bax
activation, loss of intact Bcl2 (B-cell lymphoma 2), and using
morphological criteria evident by chromatin staining or
electron microscopy as well) all show apoptosis after ischemia
(Table 2). Each of these approaches have limitations that
require consideration when studies are designed. For
example, TUNEL assays have been reported to detect necrotic
as well as apoptotic cells, and hence it cannot be used as a
sole method for quantification of apoptosis.35 Our consis-
tent approach is to combine a technique that confirms
the morphological diagnosis of apoptosis (for example,
chromatin condensation and apoptosis body formation with
Table 2 | Comparison of diagnostic methods for apoptosis
Common methods Description Limitations
DNA break assays
Terminal transferase biotin-16-
dUTP (TUNEL enzyme method)
Labeling of cells by nick
translation
Labels DNA strand breaks in cells or tissue
Labeled/stained DNA is analyzed by flow cytometry,
fluorescence microscopy, or light microscopy
TUNEL preferentially labels apoptosis in comparison with
necrosis
False positives in tissue
Also detects necrotic cells
Detection of DNA fragments Detects and quantifies fragmented DNA fragmentation by
agarose gel, radioactivity, ELISA, and so on
Genomic DNA cleaved into fragments before membrane
disintegration
Distinctive ‘ladder’ pattern consisting of fragments in multiples
of B180 bp subunits
Poor sensitivity in tissues consisting of
heterogeneous cells types and with few
apoptotic cells
Hoechst DNA staining Morphologic detection of compacted chromatin and apoptotic
bodies using fluorescence microscopy
Condensed chromatin in apoptotic cells brightly stains
Suitable for flow cytometry
Semiquantitative
Caspase activity assays Useful in cell lysates or intact cells by measuring proteolytic
cleavage of a suitable substrate (for example, PARP)
Detects apoptosis earlier than other commonly used methods
Usually a fluorometric assay
Immunoblot shows loss of intact cleavage of procaspases and
cleavage products
Most caspase substrates are cleaved by
multiple caspases
Annexin-V in plasma
membranes
Based on alterations in the asymmetry or permeability of cell
membranes due to ‘flipase’ enzyme inactivation
Phosphatidylserine translocates from the cytoplasmic side of the
membrane to the extracellular side
Annexin-V stains exposed inner membrane of
necrotic (ruptured) cells; must distinguish
apoptosis from necrosis with an additional
DNA stain (PI)
Many cells required
Cannot be used on tissue sections or fixed
samples
Electron microscopy Morphological diagnosis
Shows characteristic ultrastructure of apoptotic cell
Expensive, time consuming
Detects cells only in the terminal phase of
apoptosis
Examines only a few cells
Insensitive if few apoptotic cells are present
in sample
Detection of released
mitochondrial proteins
in the cytosol
Western blot detection of cytosolic cytochrome c and AIF
(or other intramembranous proteins)
Semiquantitative
Unsuitable for analysis of the topographic
distribution of apoptotic cells
Does not detect protein distribution in situ
Hsp60 not released unless inner membrane
is also disrupted
Detection of pro- and
anti-apoptotic protein
levels
Western blot detection of Bax, Bcl2, p53, Fas (or others) Semiquantitative
Unsuitable for analysis of the topographic
distribution of apoptotic cells
Does not detect protein distribution in situ
Abbreviations: AIF, apoptosis-inducing factor; Bcl2, B-cell lymphoma 2; ELISA, enzyme-linked immunosorbent assay; Hsp60, heat stress protein 60 kDa; PARP, poly ADP-ribose
polymerase; PI, propidium iodide; TUNEL, TdT-mediated dUTP nick end labeling.
The cellular mechanisms that result in apoptosis represent a cascade with numerous amplifying steps; many can be detected and quantified, although each approach
has its advantages and limitations. No single method unambiguously detects apoptosis. Most methods are based on the detection of one of the following: (1) DNA
fragmentation; (2) alterations in membrane asymmetry; phosphatidylserine translocates from the cytoplasmic to the extracellular side of the cell membrane; (3) activation
of apoptotic caspases; and (4) change in the level of established apoptotic proteins.
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Hoechst dye) with one or more biochemical hallmarks of
apoptosis (for example, leakage of AIF, caspase 3 or Bax
activation, and so on). Diverse antiapoptotic treatment
modalities (caspase inhibition or knockout, antagonism of
Bax, Bcl2 adenoviral delivery, erythropoietin administration,
modulation of kinases that regulate apoptosis, and induction
of endogenous, antiapoptotic stress proteins) reduce apop-
tosis in the proximal tubule in the cortex and outer medulla
and improve renal function after ischemia, as evidenced by
studies in rodents36–40 and in renal epithelial cells in vitro.41,42
In renal and non-renal cells, the mitochondrion is a key
site for integrating intrinsic and extrinsic pro- and anti-
apoptotic signals during stress. Ultimately, the balance between
pro- and anti-apoptotic forces (the ‘apoptotic rheostat’43)
determines whether or not the cells die by opening ‘Pandora’s
Box’—the outer mitochondrial membrane.44 Mitochondrial
membrane permeabilization is regulated by BCL2 family
proteins that number at least 20 (see Youle and Strasser45).
Protecting the mitochondrial membrane is crucial, because
stress-induced permeabilization permits proapoptotic pro-
teins (cytochrome c, AIF, and others, including Omi/HtrA2
(Kim et al.46) to activate caspase-dependent and -indepen-
dent pathways.47 In renal epithelial cells, Bax and Bak are the
primary BCL2 members that increase membrane perme-
ability, whereas Bcl-2 and Bcl-XL (B-cell lymphoma-extra
large) antagonize ‘membrane attack’ by Bax and Bak. Both
metabolic stress in vitro8,48–50 and renal ischemia in vivo1,36,51
increase the Bax/Bcl2 ratio, a primary determinant of cell
death.52 In renal cells, ischemia activates Bax42,53 and reduces
Bcl2,36,54 markedly altering the Bax/Bcl2 ratio in a pro-
apoptotic direction.50 Interestingly, both Bax and Bcl2 mRNA
levels are markedly increased in regenerating proximal tubule
cells up to 7 days postischemia.55 This finding suggests that a
delicate interplay between anti- and pro-apoptotic members
of the BCL2 family is necessary for repair in damaged
proximal tubule cells after an ischemic insult. Mitochondrial
membrane injury has also been attributed to other members of
the BCL2 family including t-Bid, the active form of Bid.56
However, Bax/Bak double-knockout cells52,57 or mice58 exhibit
resistance to apoptotic stimuli, suggesting that Bax, perhaps in
conjunction with Bak, is the primary BCL2 family member
responsible for outer mitochondrial membrane damage.59 This
conclusion is consistent with the recent observation that Bid
knockout briefly delays but does not prevent death from renal
failure in mice subjected to bilateral renal occlusion.60 Bad and
Bim, two other BH3-only members of the BCL2 family, bind
certain antiapoptotic BCL-2 proteins (Bcl-2, Bcl-XL) and
block their pro-survival functions. For example, Bad binds
Bcl-XL, inhibiting its antiapoptotic function. In contrast, Bad
phosphorylation by Akt (protein kinase B) releases Bcl-XL and
promotes cell survival.52,61,62
Stress kinases, including, but not limited to, AKT,
glycogen synthase kinase 3-b (GSK3b), and Jun-N-terminal
kinase, regulate apoptosis through phosphorylation, cleavage,
or conformational change, and/or by releasing proapoptotic
BCL2 proteins and by either inactivating or degrading
antiapoptotic family members (Figure 1).52,63 Specific cell
stressors appear to determine which members of the family
are activated.
GSK3b is a key mediator of ischemic mitochondrial injury
and apoptosis in proximal tubule cells, and appears to be a
readily modifiable cell survival signal after an acute ischemic
episode. GSK3b promotes Bax-mediated apoptosis caused by
ATP depletion in vitro as well as after renal ischemia in vivo
and contributes to tubular injury and organ dysfunction.64
Expression of a constitutively active GSK3b mutant acti-
vates Bax and decreases cell survival after ischemia, partly
by altering Bax serine phosphorylation.64,65 In contrast,
pharmacologic inhibition (4-benzyl-2-methyl-1,2,4-thiadia-
zolidine-3,5-dione (TDZD-8)) or RNA interference-medi-
ated knockdown of GSK3b promotes renal epithelial cell
survival. In rats, TDZD-8 treatment inhibits ischemia-
induced activation of GSK3b, Bax, and caspase 3, ameliorates
tubular and epithelial cell damage, and preserves renal
function. Importantly, GSK3b inhibitors could be used in
prevention or treatment of AKI in humans.64 In addition to
its effect on Bax serine phosphorylation, TDZD-8 could also
afford renoprotection by GSK3b-independent mechanism(s)
including cell proliferation, an important determinant of
renal repair, or by reducing ischemia-induced inflammation.
GSK3b inhibitors also improve renal outcome in endo-
toxemia-induced AKI in rats,66 further underscoring their
importance as possible therapeutic interventions. During
ischemia, mitochondrial morphology completely changes:
the filamentous mitochondria undergo extensive fission,
resulting in organelle fragmentation (Figure 2). In fact,
fragmentation was detected in murine proximal tubular
mitochondria after renal ischemia and cisplatin nephrotoxi-
city.67 It now appears that mitochondrial fragmentation is a
relatively early event that precedes outer mitochondrial
membrane disruption, Bax activation, and apoptosis. However,
it is not yet known whether or not this morphological change
increases the sensitivity of the mitochondria to apoptosis. A
recent study suggests that pro-apoptotic Bak participates in
mitochondrial fragmentation.68 Adding to the conundrum is
the observation in healthy non-renal cells that some BCL2
proteins actually promote mitochondrial fusion.69
In addition, renal tubular cells also express cell surface
‘death receptors’ of the tumor necrosis factor (TNF) super-
family including Fas, TNF receptor 1, and Fn14 receptor that
also induce apoptosis.28 Fas ligand, TNF, and TNF-like weak
inducer of apoptosis (TWEAK, TNFSF12) activate caspases
and initiate apoptosis by binding to distinct receptors during
renal ischemia, presumably contributing to AKI.3,70 This
hypothesis is supported by a report that RNA interference
directed against Fas ameliorates murine I/R injury.71 TNF
also increases the expression of apoptosis-related molecules
that contribute to its cytotoxic effect.7 Other external
circulating substances, including specific growth factors,
suppress apoptosis under normal conditions.72 Growth factor
deficiency induces apoptosis in tubular epithelial cells (and
other cells) partly by changing the expression level of
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pro- and anti-apoptotic BCL2 proteins.73 The concentration
of epidermal growth factor in the serum and urine decreases
both during and after ischemic acute renal failure,3 suggest-
ing that growth factor deficiency accompanies reperfusion,
potentially slowing recovery of organ function by causing
apoptosis. The loss of growth factors could be partly
responsible for the ‘second wave’ of apoptosis reported after
ischemic injury, although this has not been formally tested.
However, administration of exogenous epidermal growth
factor and other growth factors (for example, insulin-like
growth factor, hepatocyte growth factor, and vascular
endothelial growth factor) decreases apoptosis and accele-
rates recovery after ischemic acute renal failure,62,74–77
suggesting that apoptosis determines organ function during
the recovery phase. This anti-apoptotic, cytoprotective effect
of growth factors is partially mediated by the phosphatidyl-
inositol 3-kinase/AKT pathway.5,75 AKT phosphorylates
transcription factors and numerous downstream kinases
Nucleus
DNA fragmentation
DNA damage
Apoptosis
MPT
ROS
ROS
Mitochondrion
Cyto c AIF
AIFCaspase
activation
Fas ligand
TNF-α
TWEAK
Cellular stress
Growth hormones
survival factors
cytokines
JNK
BakBax
Caspase 8, 10
Bid
t-Bid
Bcl2
PI3k
Hsp27
GSK3βAkt
Hsp70
Hsp70
Hsp27
ERK1/2
Bad
BIM
p38
p53
Toxins
t-Bid
ROS
Figure 1 | Simplified representation of major intrinsic and extrinsic signal events known to promote apoptosis in renal cells
exposed to stress. Life and death signals are integrated by the mitochondrion and determine whether or not MPT occurs, resulting in the
release of both caspase-dependent and -independent factors that promote apoptosis from the intramembranous space. Caspase activation
and DNA fragmentation produce many of the characteristic morphological changes associated with apoptotic cell death after exposure to
stress, nephrotoxins, ROS, DNA injury, activation of stress kinases, or removal of extrinsic factors that normally suppress apoptosis. AIF,
apoptosis-inducing factor; Akt, protein kinase B; Bax, Bad, Bak, BID, and truncated or t-Bid are proapoptotic BCL2 proteins; Bcl2, anti-
apoptotic BCL2 protein; Cyto c, cytochrome c; ERK1/2, extracellular regulated kinase 1/2; FasL or CD95, FAS ligand; GSK3b, glycogen
synthase kinase 3-b; Hsp, heat stress protein; JNK, Jun-N-terminal kinase; MPT, outer mitochondrial membrane pore transition; p38,
mitogen-activated protein kinase; p53, a tumor-suppressor protein; PI3k, phosphatidylinositol 3-kinase; ROS, reactive oxygen species
generated by mitochondria or other sources; TNF-a, tumor necrosis factor-a; TWEAK, TNF-related weak inducer of apoptosis. ERK1/2 and
JNK are stress-regulated kinases; Hsp70 is heat stress protein 70 kDa, an antiapoptotic protein; Hsp27 is heat stress protein 27 kDa; FasL
or CD95 is a TNF family member.
Control ATP deplete
Figure 2 |Mitochondrial morphology in primary proximal tubule cells at baseline (Control) and during adenosine-5’-triphosphate
(ATP) depletion using MitoTracker red (Invitrogen, Carlsbad, CA). Filamentous mitochondria undergo fragmentation, resulting in small,
punctuate organelles during ATP depletion; an in vitro model of ischemic injury.
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with anti-apoptotic effects on Bax.78 In contrast to protective
growth factors, transforming growth factor-b1 induces
apoptosis in renal tubule cells both in vitro and in vivo,76,77
and its level increases during I/R.75 Together, these observa-
tions show that the balance between pro- and anti-apoptotic
growth factors is an important determinant of renal epithelial
cell survival and kidney function post-ischemia.
The widespread use of renal replacement therapy in severe
ischemic AKI has not reduced the associated risk of
death.79,80 This startling observation has prompted the
investigation of potential systemic consequences of renal
ischemia. In fact, transient renal ischemia induces a similar
‘transcriptome’ in the rodent kidney and lung with the
elaboration of 4100 genes and specific interleukins in both
organs.81 Kelly and colleagues82 reported that renal ischemia,
independent of azotemia, caused distinct systemic events,
including an increase in TNF-a, interleukin-1, and mRNA
coding for leukocyte intracellular adhesion molecule-1.
Interestingly, these systemic changes are associated with loss
of cardiac contractility, increased leukocyte infiltration, and,
importantly, an increase in myocardial cell apoptosis that is
diminished by a TNF inhibitor.82 These findings suggest that
renal ischemia initiates biochemical signaling events in
distant organs (lung, heart, liver, and brain) that cause
extrarenal apoptosis and inflammation. If similar systemic
signal events occur in humans, then these observations may
partly explain the limited value of dialysis as the sole
therapeutic modality for acute ischemic AKI.
In addition to renal epithelial cells, recent evidence shows
that renal ischemia targets non-epithelial cells, especially
endothelial cells of the microvasculature of the vasa recta, and
contributes to early post-ischemic organ dysfunction.83,84
Specifically, dysfunction and death of vascular endothelial
cells compromise the permeability barrier at the level of the
peritubular capillaries and increase glomerular filtrate back-
leak. Both ischemia itself and postischemic inflammatory
molecules and cells contribute to endothelial cell injury. At
present, it is unclear whether or not endothelial cell apoptosis
contributes to organ failure84 by initiating epithelial injury
via a paracrine pathway, releasing RNA carrying micro-
vesicles,85 or is simply another compartment targeted by
I/R.83,84
Importantly, all mammalian cells contain inducible
cytoprotective proteins that promote survival during stress
leading to apoptosis.86 Heat stress proteins (HSPs), named
for their marked induction by hyperthermia, include Hsp70,
the most abundant and well-characterized stress-inducible
protein. A pro-survival role of Hsp70 in the kidney has been
suspected for years because it is markedly induced in rodents
by brief renal ischemia,87 and its induction increases renal cell
resistance to subsequent stress. Mild, transient renal ischemia
sufficient to increase Hsp70 expression increases resistance to
subsequent ischemia-induced organ failure up to 8 days
later.88 Interestingly, ureteric obstruction also confers ‘cross-
tolerance’ to ischemic injury.88 Pharmacologic Hsp70 induc-
tion by geranylgeranylacetone, a nontoxic agent, preserves
renal function in rats if administered before ischemia.89
Furthermore, in preliminary experiments performed in our
laboratory using Hsp70þ /þ , Hsp70/, and Hsp70þ /þ
transgenic mice, loss of renal Hsp70 resulted in a step-wise
increase in the ratio of active Bax/Bcl2 and the severity of
ischemic organ failure.90 Finally, selective expression of
Hsp70 in primary proximal tubule cells harvested from
Hsp70/ mice prevents apoptosis caused by ATP depletion.
In renal cells, protection by Hsp70 is partly because of its
ability to prevent the outer mitochondrial membrane attack
by Bax and also by cytosolic sequestration of AIF, a pro-
apoptotic mitochondrial protein.41,91 Protection by Hsp70,
termed a ‘classic molecular chaperone’, is complex and its
nonchaperone functions also exert antiapoptotic effects.42
Human Hsp27 (and its murine homolog, Hsp25), a small
HSP, inhibits ATP depletion-induced apoptosis in vitro and
improves renal function after I/R in vivo.53,92 Hsp27, an
inducible cytoprotectant like Hsp70, opposes apoptosis via
phosphatidylinositol 3-kinase, a kinase upstream of Akt and
GSK3b, the two inter-related but opposing enzymes that
regulate Bax.53 Taken together, these studies suggest that HSP
induction is promising for the prevention and treatment of
human ischemic AKI.
Oxidative stress plays an important role in renal apoptosis,
especially during reperfusion. Either by acting as signal
transduction molecules or by directly causing cellular
damage, reactive oxygen species (ROS) activate apoptosis at
multiple steps in the cell death pathway (Figure 1).36,93
Although reduction of ROS production or ROS scavengers
protect against insults in cell culture experiments, in vivo data
have been disappointing (see ‘Therapeutic Implications’
below).
RENAL APOPTOSIS IN SEPTIC SHOCK
Septic shock is a leading cause of AKI in the intensive care
setting and contributes to the high rate of morbidity and
mortality, especially in the setting of multiorgan failure.94
Sepsis-induced renal dysfunction was initially believed to be
hemodynamic in origin and, consequently, most therapeutic
efforts have focused on increasing perfusion pressure and
renal blood flow. However, animal experiments and some
human data suggest that renal blood flow is not necessarily
decreased in all cases. In fact, renal blood flow increased or
was normal in certain animal models and in some septic
patients.94–98 Furthermore, renal biopsies in patients with
septic shock not only show acute tubular necrosis due to
hypoperfusion, but also evidence pronounced capillary
leukocyte infiltration and epithelial cell apoptosis.97 The
pathogenesis of septic AKI is clearly multifactorial but
definitely involves renal cell apoptosis.94,97–99
The injured kidney not only initiates untoward biochem-
ical signaling events in distant organs, but may be an
unfortunate recipient of such stimuli. Cultured tubular cells
and podocytes treated with plasma from patients with severe
burns and sepsis-associated AKI undergo apoptosis, suggest-
ing that circulating systemic factors cause apoptosis in the
34 Kidney International (2011) 80, 29–40
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kidney.100 Lipopolysaccharide, a well-known circulating
endotoxin and a component of the bacterial cell wall, is a
major cause of septic shock and potentially causes acute renal
failure by inducing apoptosis in tubular cells either directly or
via systemic cytokine release.101,102 The role of tubular cell
apoptosis in lipopolysaccharide-induced AKI is underscored
by experiments in mice showing that caspase inhibition
protects against lipopolysaccharide-induced acute renal fail-
ure. Interestingly, caspase inhibitors not only prevented
apoptotic cell death in this model but also decreased
inflammation in the kidney,103 confounding interpretation
of whether one or both lesions contribute to organ failure. As
in ischemia, GSK3b is also activated in endotoxemia and
contributes to AKI by promoting inflammation and apop-
tosis. In mice, GSK3b inhibitors decreased renal cell
apoptosis and improved both organ function and animal
survival after endotoxemia by downregulating proinflamma-
tory cytokines including TNF-a, a key regulator of inflam-
mation and apoptosis.104,105
In addition to epithelial cell damage, the endothelium is
also targeted by sepsis. Endothelial cell injury disrupts
microvascular blood flow, causing renal hypoperfusion,
hypoxia, and epithelial cell ischemia. Disruption of the
endothelial cell layer leads to increased vascular permeability
and ‘backleak’ of glomerular filtrate as well as leukocyte
recruitment and activation that facilitate inflammation and
organ injury. These processes likely decrease GFR in septic
AKI. During Gram-negative sepsis, both circulating bacterial
lipopolysaccharide and TNF-a induce apoptotic cell death in
glomerular endothelial cells in vitro and may contribute to
sepsis-induced AKI in vivo.106,107 TNF-a signaling through
TNF-a receptor 1 in renal endothelial cells induces apoptosis
via a caspase-8-dependent pathway.105 In theory, extracor-
poreal removal of circulating cytokines, pharmacologic
cytokine suppression, or administration of other anti-apoptotic
mediators could preserve organ function. Unfortunately,
experimental or clinical data to support this hypothesis are
presently lacking.108,109
TOXIC RENAL INJURY AND APOPTOSIS
Abundant evidence shows that apoptotic cell death is a
prominent and characteristic feature of AKI caused by
nephrotoxic medications, pigments (hemoglobin or myoglo-
bin), and/or intravenous contrast agents.5,9,110,111 Cisplatin, a
well-characterized chemotherapy agent that is frequently
employed in experimental AKI, induces both acute and
chronic kidney injury that limits its efficacy as an anticancer
treatment. Together, tubular epithelial cell toxicity, vasocon-
striction of the renal microvasculature, and inflammation
contribute to cisplatin-induced AKI. The risk of AKI is
increased with high peak plasma-free platinum concentra-
tions, previous exposure to cisplatin, concomitant use of
other nephrotoxins, and pre-existing chronic kidney disease.
As a result of renal uptake by organic cation transporters, the
concentration of platinum in the renal cortex is several fold
greater than that in the plasma and other organs.112 Cisplatin
decreases the GFR primarily by injuring the S3 segment of the
proximal tubule and the distal nephron.110 Although DNA is
the primary biological target of cisplatin, it has several other
intracellular targets. For example, cisplatin inhibits mito-
chondrial F1F0-ATPase, thereby reducing mitochondrial
oxidative phosphorylation and membrane potential; two
intracellular events that precede cytochrome c release and
apoptotic cell death. Activation of the p38 mitogen-activated
protein kinase-mediated apoptotic cell death pathway and
oxidative stress are among the earliest renal responses to
cisplatin. In mice, the p38 and extracellular regulated kinases
1/2 mitogen-activated protein kinase pathway function is an
upstream signal for TNF-a-mediated inflammation as well as
caspase 3-mediated apoptosis.113 In rats, N-acetylcysteine
inhibits these cytotoxic processes and prevents cisplatin-
induced apoptosis.114
Cisplatin nephrotoxicity is characterized by activation of
both pro-inflammatory cytokines and chemokines. The
importance of TNF-a in cisplatin-induced AKI is supported
by in vivo experiments wherein cisplatin treatment induces
TNF-a production in mice, and TNF-a inhibitors ameliorate
cisplatin-induced renal dysfunction and apoptosis. Impor-
tantly, TNF-a-deficient mice are resistant to cisplatin
nephrotoxicity.115 However, these experiments do not
address the question of whether TNF-a induces renal injury
by directly activating the extrinsic pathway of apoptosis or by
inducing a local inflammatory response in the renal
cortex.113,115,116
Experiments in vitro and in vivo also show that p53, a
tumor-suppressor protein that is normally undetectable, is
markedly induced by cisplatin. As a result, key executioner
caspases under the transcriptional control of p53 (caspase-6
and caspase-7) cause apoptosis via the mitochondrial path-
way.117 Other caspases are clearly involved in cisplatin-
mediated renal injury because less tubular apoptosis,
neutrophil infiltration, and improved renal function were
observed in caspase-1 knockout mice.38
Similar to ischemia, cisplatin alters the expression of cell
cycle proteins. For example, both the cyclin-dependent kinase
2 and its inhibitor, p21, are activated during cisplatin
treatment in vitro and in vivo, thereby inducing apoptosis
by altering the balance between cyclin-dependent kinase 2
and p21. Interestingly, p21 is induced during cisplatin
nephrotoxicity via both p53-dependent and -independent
mechanism.116,118,119
Cisplatin also causes outer mitochondrial membrane
injury by activating pro-apoptotic proteins, Bax and Bak.
Bax knockout mice are partially protected from cisplatin
toxicity, emphasizing the central role of Bax-induced
apoptosis in this model.120,121 Mitochondrial membrane
injury releases cytochrome c, AIF, Smac/DIABLO, as well as
other apoptotic mediators. Cytosolic cytochrome c activates
caspase-9, causing caspase-dependent apoptosis. Meanwhile,
AIF translocates to the nucleus and initiates the caspase-
independent pathway of apoptosis by causing DNA frag-
mentation and chromatin condensation.116
Kidney International (2011) 80, 29–40 35
A Havasi and SC Borkan: Apoptosis and AKI r ev iew
Mitochondrial dysfunction resulting from cisplatin also
increases ROS, contributing to tubular cell damage and
apoptosis.121 Although the mechanism is incompletely
characterized, a decline in mitochondrial membrane poten-
tial coupled with depletion of the organelle antioxidants (for
example, glutathione) likely enhances ROS production.110,116
Cisplatin induces oxidative damage to mitochondrial lipids
and proteins that parallels the increase in caspase-3 activity
and apoptotic renal cell death.122 These intriguing observa-
tions suggest that mitochondria, Bax, caspases, ROS, and
oxidant defense are each potential targets for improving the
clinical outcome in cisplatin-induced nephrotoxicity.
Cyclosporin A, a widely used transplant medication, has
similar toxic effects on tubular epithelial cells as cisplatin. In
addition, it increases Fas expression and decreases the level of
Bcl-XL (an antiapoptotic protein), activating caspase-3 and
caspase 9 to cause apoptosis.6
Apoptosis also contributes to AKI caused by rhabdo-
myolysis-induced myoglobinuria. Myoglobin is toxic to the
tubular cells, partly by altering interaction between the stress
kinase Jun-N-terminal kinase and 14-3-3, two proteins that
promote apoptosis by enhancing the toxicity of BCL2
proteins (Bax, Bid, and Bad;52,123) that promote outer
mitochondrial membrane injury and caspase activation.124
THERAPEUTIC IMPLICATIONS
Despite the current absence of human trials, several
therapeutic interventions targeting the apoptotic pathway
have shown beneficial effects in animal models (Table 3). To
improve the efficacy of antiapoptotic therapy, the following
will be needed: (1) renal-specific interventions; (2) selective
targeting to the relevant renal cell types most susceptible to
apoptosis; and (3) improved understanding of the potential
‘double-edged apoptotic sword’ that affords both beneficial
and untoward consequences.5 Solutions to each of these
challenges are likely. For example, the presence of specific
transporters on multiple renal cell types (for example,
proximal epithelial and vascular endothelial cells) could be
utilized to achieve cell-specific targeting. Timing and
selection of interventions including RNA interference,71
transcription factors,125 or therapeutic peptides126 can be
refined.
To date, investigators have shown in animals that caspase
inhibitors, such as zVAD, decrease apoptosis and improve
organ function in diverse AKI models9,127 and warrants
further investigation. Caspase inhibitors have also been
shown to prevent I/R injury in organs other than the kidney.128
Because caspase inhibition also reduces renal inflammation that
accompanies I/R or sepsis-induced AKI,103,105 it is not yet clear
whether apoptosis or inflammation is the more relevant
pathophysiological process. Caspase activity could be indirectly
modulated by targeting its upstream regulators such as MEK or
GSK3b. For example, the MEK inhibitor U0126 provides
functional and histological protection in toxic AKI by
decreasing caspase-3-induced apoptosis.113 Unfortunately,
known inhibitors of upstream kinases involved in apoptosis
lack specificity and often have untoward side effects. It is also
worth noting that individual caspases have distinct functions:
some inactivate structural and regulatory proteins (for
example, degradation of actin and lamins or inactivation
of poly (ADP-ribose) polymerase (PARP)) whereas others
activate caspase substrates (for example, other caspases or
pro-apoptotic factors such as BID). In addition to the well-
characterized role of caspases in apoptosis, growing evidence
suggests their participation in other cellular processes such
as development, cell cycle, cell migration, and receptor
internalization.129 This complicates accurate predictions of
clinical efficacy of pancaspase inhibitors in human trials.
Development of specific inhibitors directed against select
caspases involved only in the cell death pathway could
overcome this problem.
TDZD-8, a pharmacologic inhibitor of GSK3b, a potent
proapoptotic kinase, ameliorates proximal tubular epithelial
cell apoptosis and improves GFR by nearly 40% when
administered to rats before transient bilateral renal artery
occlusion.64 It is also likely that TDZD-8 exerts other
beneficial effects in the kidney by suppressing inflammation
and enhancing renal cell proliferation,130 and represents a
rational class of agents in human trials designed to prevent or
treat AKI.
Table 3 | Possible therapeutic interventions for improving
outcome in AKI
Modifiable pathways Therapeutic intervention
Intrinsic apoptotic
pathway
Caspase inhibition (zVad, a pancaspase
inhibitor)
siRNA, oligo (Bax, Bad)
Overexpression (Bcl-XL)
Mitoprotective peptides
Antiapoptotic kinases PI3k/Akt antiapoptotic pathway activators
Proapoptotic kinases JNK inhibitors
GSK3b inhibitors
Survival factors IGF-1 administration
VEGF administration
Cytokines death
receptors
Pentoxifylline (inhibits TNF-a production)
Anti-Fn14 blocking monoclonal antibody
Tumor-suppressor
proteins
p53 inhibitors (pifithrin-a)
Oxidative stress Inhibition of ROS production (xanthine
oxidase inhibitors, deferoxamine)
Antioxidant enzymes (SOD, SOD mimetics)
ROS scavengers (tempol, uric acid, mannitol,
ascorbinic acid, edaravone)
N-acetylcysteine, taurine
Resveratrol
Cell cycle proteins Modulators of p21 and cdk2
Heat stress proteins Heat or cold preconditioning
Hsp inducers (geranylgeranylacetone)
Abbreviations: AIF, apoptosis-inducing factor; AKI, acute kidney injury; Akt, protein
kinase B; Bcl-XL, B-cell lymphoma-extra large; cdk2, cyclin-dependent kinase 2;
GSK3b, glycogen synthase kinase 3-b; Hsp, heat stress protein; IGF-1, insulin-like
growth factor 1; JNK, Jun-N-terminal kinase; PI3k, phosphatidylinositol 3-kinase;
ROS, reactive oxygen species; siRNA, small interfering RNA; SOD, superoxide
dismutase; TNF-a, tumor necrosis factor-a;VEGF, vascular endothelial growth factor.
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Because ROS production promotes apoptosis and plays a
deleterious role in several AKI models, it seems rational to
use drugs that inhibit ROS production or scavenger ROS
to prevent or treat organ injury. Various antioxidants have
been successfully used to prevent ischemic, septic, or toxic
(gentamicin or cisplatin) AKI in animal models.4,9,73,110
However, these interventions are currently limited to preven-
tion, rather than treatment of renal injury. Several ROS
scavengers including mannitol,131 uric acid,131 edaravone,132
bilirubin (at mmol/l concentrations;133), stobadine,134 resver-
atrol,135 and quercetin136 show benefit in animal models of
renal I/R. Deferoxamine, N-acetylcysteine, and allopurinol,
commonly used medications, prevent ROS generation137–139
and apoptosis in murine models of I/R, although human
studies did not reproduce these positive results.140 In animal
models, administration of antioxidant enzymes (superoxide
dismutase or its mimetics such as EUK-134 and tempol141)
that degrade ROS are also beneficial. The potential benefits of
systemic clinical administration of these agents have been
limited because of their rapid proteolytic degradation,
immunogenicity, and pro-oxidant activities observed at high
concentrations.142 To date, antioxidant pharmacological
interventions have proven to be unsuccessful in clinical trials.
Modulation of the growth factor/cytokine milieu in the
kidney in a manner that inhibits apoptosis could also alter
the course of AKI. In vivo, these mediators originate from the
renal cells themselves, outside the kidney (circulating factors)
or from infiltrating leukocytes. Exogenous epidermal growth
factor administration improves renal tubular cell regenera-
tion,75,143 and pre-ischemic insulin-like growth factor 1 treat-
ment inhibits apoptosis in murine models of I/R and
cisplatin-induced nephrotoxicity and apoptosis9,37 by acti-
vating the phosphatidylinositol 3-kinase/Akt pathway.9,62
Similarly, vascular endothelial growth factor protects against
cyclosporine A-induced tubular cell apoptosis in vivo.74
Unfortunately, insulin-like growth factor 1 has failed to
reduce AKI in clinical trials.144 Pentoxifylline prevents AKI of
diverse etiologies, presumably by inhibiting TNF-a produc-
tion, thereby dampening the death receptor-mediated
apoptosis,145 and may have clinical applications. However,
targeting the death receptor pathway for therapeutic inter-
vention is complicated by the fact that it is also necessary for
the normal regulation of the immune system.
SUMMARY
Apoptosis occurs in both human and animal kidneys during
AKI. Specifically, apoptosis can be detected in the kidneys
after ischemia, toxin exposure, inflammation, and sepsis.
Many of these insults occur simultaneously in humans in the
intensive care setting and appear to be part of systemic
disease process that involves circulating cytokines, TNF-a,
and leukotrienes. Although multiple processes that target
renal endothelial and epithelial cells as well as the inflam-
matory pathway contribute to the loss of organ function in
AKI, it is increasingly clear that apoptosis contributes to renal
failure. Despite its evanescent nature, and the absence of
sensitive techniques for detection, therapy directed at
apoptosis is rational. Several key questions for experimen-
talists remain: (1) Does apoptosis serve two ‘masters’: is it
a ‘killer’ of renal and other cells and/or an ‘architect’ of
remodeling? (2) What is the optimum ‘window of oppor-
tunity’ for anti-apoptotic maneuvers and will they be
effective both before and after AKI? (3) Can anti-apoptotic
agents be used in conjunction with emerging cell targeting
techniques to minimize untoward side effects? Answers to these
questions are required before we can prescribe antiapoptotic
therapies to prevent or cure human AKI, but we are clearly
closer to understanding this intriguing biological puzzle.
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